Clinical Trial Update: Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1) [Phase 3]

View source ↗

Summary

A Phase 3 trial (LUME-Colon 1) comparing nintedanib (BIBF 1120) to placebo in refractory metastatic colorectal cancer has completed and posted results in July 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Colorectal Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2017-07-21